TheraPrint® for Breast or Colorectal Cancer

Clinically Relevant Biomarker Analysis to Individualize Cancer Treatment



agendia®

decoding cancer

TheraPrint® Your Roadmap to Targeted and Alternative Treatment Planning

- **Complements traditional tools to facilitate decision making**
- **Assesses relevant biomarkers at the RNA and DNA level**
- **Correlates results with likely response or resistance to treatment**
  - **Some markers are directly targeted by existing drugs**
  - **Others are directly involved in resistance or response mechanisms**

A greater level of personalized treatment

The promise of individualized therapy starts with an understanding of the underlying biology of a patient's tumor. Armed with this information, physicians are able to offer patients access to novel therapies and to select treatment that is more tailored toward the patient's individual tumor.

A comprehensive assessment

With an expanding arsenal of therapies, an understanding of the molecular changes driving the patient's tumor growth is required to select appropriate treatment.

An individualized genomic fingerprint

TheraPrint provides individualized gene expression results for dozens of relevant biomarkers–along with variant analysis for four genes–to interrogate each tumor.

Correlated with potential therapies and clinical trials

This unique genomic fingerprint of the tumor is then matched with potential target therapies and trials. The results are based upon extensive review of global clinical literature correlating specific biomarkers to drug sensitivity or resistance.

Actionable results

TheraPrint's actionable results can be used to guide treatment selection within the standard of care, as well as to reveal alternatives when the standard of care has been exhausted, when there are comorbidities, or in cases of highly aggressive, rare or unresectable tumors.



Analysis of markers that indicate likely response or resistance to a variety of therapies

Breast

TheraPrint for breast cancer provides an individualized genomic fingerprint of the patient's tumor with gene expression results for 55 biomarkers and variant analysis results for 4 genes identified as potential markers for predicting response to a variety of hormonal, chemical, and biological therapies.

55 Biomarkers
with variant analysis for
4 key genes

Colorectal

TheraPrint for colorectal cancer provides an individualized genomic fingerprint of the patient's tumor with gene expression results for 39 biomarkers and variant analysis results for 4 genes that have been identified as potential markers for predicting response to a variety of chemical and biological therapies.

39 Biomarkers
with variant analysis for
4 key genes

THERAPY	BREAST CANCER	COLORECTAL CANCER
ENDOCRINE THERAPY		
Anti-Androgen	●	
Aromatase inhibitors	●	
SERM	●	
CHEMOTHERAPY		
Alkylating Agents	●	●
Anthracyclines	●	●
Anti-metabolites	●	●
General	●	●
Mitotic inhibitors/Taxanes	●	●
Platinum Based	●	●
Topoisomerase inhibitors	●	●
TARGETED THERAPY		
Angiogenesis inhibitor	●	●
Anti-EGFR inhibitors		●
DNA Repair System Modulators/PARP inhibitors	●	●
EGFR-downstream inhibitors	●	●
HER2/EGFR inhibitors	●	
HER2/PI3K-downstream Pathway inhibitors	●	
Kinase inhibitors and other pathways		●
Other Kinase inhibitors	●	
OTHER		
BH3 Mimetic	●	●
Bisphosphonates or Diphosphonates	●	
Cox2 inhibitors		●
Demethylating Agents	●	
IGFR inhibitor	●	●
Inhibitors of Apoptosis Proteins Antagonists	●	●
Proteosome inhibitor	●	●
SMO Antagonist		●
TGF-beta inhibitors		●

Comprehensive TheraPrint® results are provided in an easily referenced report along with expert clinical interpretation by a medical oncologist

The report includes the patient's results for all biomarkers and a clinical relevance statement with a short description of how expression and mutation presence are linked to response or resistance to the associated drugs. Additional detailed clinical and biological background information about each marker, drug names and literature references are available to the ordering physician.



Legend

Expression: Low — High

Low expression on left of bar.
High expression on right of bar.

Color Gradient:
- Green = Sensitivity
- Blue = Resistance

Color Density:
- High expression sensitivity
- Low expression sensitivity
- High expression resistance
- Low expression resistance

Color density indicates strength of association with drug response.

Patient Score: X

Individual patient score for expression indicated with "X".

Variant Analysis:
Indicates presence of wildtype or specific mutation with associated drug response.

wt

e.g. Wildtype (wt) green indicates likely sensitivity to drug

His 1047 Arg

e.g. Mutation at H1047 indicates likely resistance to drug

- ● ● ● = Level 3 (Relevance shown in clinical trials)
- ● ● ○ = Level 2 (Multiple studies showing cause-effect between gene activity and drug response)
- ● ○ ○ = Level 1 (Pre-clinical studies or studies in other cancers showing relevance of marker)
- ○ ○ ○ = Level 0 (Strong biological indication but no direct evidence)

agendia®
decoding cancer

US: 22 Morgan | Irvine | CA | 92618 | Ph. 888.321.2732 | Fax 866.756.7548 | customercare@agendia.com | www.agendia.com
Outside US: Agendia NV | Science Park 406 | 1098 XH Amsterdam | The Netherlands | Ph. +31 (0) 462 1500 | customerservice@agendia.com | www.agendia.com